Skip to main content
Log in

Current Status of Interventional Radiology in the Management of Gastro-Entero-Pancreatic Neuroendocrine Tumours (GEP-NETs)

  • Review
  • Published:
CardioVascular and Interventional Radiology Aims and scope Submit manuscript

Abstract

Within the group of Gastro-Entero-Pancreatic Neuroendocrine tumours (GEP-NETs), several heterogeneous malignancies are included with a variety of clinical manifestations and imaging characteristics. Often these cases are inoperable and minimal invasive treatment offered by image-guided procedures appears to be the only option. Interventional radiology offers a valid solution in the management of primary and metastatic GEP-NETs. The purpose of this review article is to describe the current status of the role of Interventional Radiology in the management of GEP-NETs.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Amodio A, Crosetti S (2010) Tumori Neuroendocrini. In: Lopez M, Gebbia N, Cascinu S, Marchetti P (eds) Oncologia Medica Pratica. Società Editrice Universo, Roma, pp 2173–2194

    Google Scholar 

  2. Muniraj T, Vignesh S, Shetty S et al (2013) Pancreatic neuroendocrine tumor. Dis Mon 59:5–19

    Article  PubMed  Google Scholar 

  3. Colao A, Faggiano A, Milone F (2011) Tumori Neuroendocrini. In: Lenzi A, Lom-bardi G, Martino E, Vigneri R (eds) Endocrinologia Clinica. Edizioni Minerva Medica, Torino, pp 217–224

    Google Scholar 

  4. Klöppel G (2011) Classification and pathology of gastroenteropancreatic neuroendocrine neoplasms. Endocrine Related Cancer 18:S1–S16

    Article  PubMed  Google Scholar 

  5. Bosman FT, Carneiro F, Hruban R et al (2010) WHO classification of tumours of the digestive system. IARC Press, Lyon

    Google Scholar 

  6. Klimstra DS, Modlin IR, Coppola D et al (2010) The pathologic classification of neuroendocrine tumors: a review of nomenclature, grading, and staging systems. Pancreas 39:707–712

    Article  PubMed  Google Scholar 

  7. Yao JC, Hassan M, Phan A et al (2008) One hundred years after “carcinoid”: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol 26(18):3063–3072

    Article  PubMed  Google Scholar 

  8. Burns WR, Edil BH (2011) Neuroendocrine pancreatic tumors: guidelines for management and update. Curr Treat Options Oncol 13:24–34

    Article  Google Scholar 

  9. Orgera G, Krokidis M, Monfardini L et al (2011) High intensity focused ultrasound ablation of pancreatic neuroendocrine tumours: report of two cases. Cardiovasc Intervent Radiol 34:419–423

    Article  PubMed  Google Scholar 

  10. Drymousis P, Raptis DA, Spalding D et al (2014) Laparoscopic versus open pancreas resection for pancreatic neuroendocrine tumours: a systematic review and meta-analysis. HPB (Oxford) 16(5):397–406

    Article  Google Scholar 

  11. Rossi RE, Massironi S, Spampatti MP, Conte D, Ciafardini C, Cavalcoli F, Peracchi M (2012) Treatment of liver metastases in patients with digestive neuroendocrine tumors. J Gastrointest Surg. 16(10):1981–1992

    Article  PubMed  Google Scholar 

  12. Oberg K, Knigge U, Kwekkeboom D, ESMO Guidelines Working Group et al (2012) Neuroendocrine gastro-entero-pancreatic tumors: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 23(Suppl 7):vii124–vii130

    PubMed  Google Scholar 

  13. Pavel M, Baudin E, Couvelard A et al (2012) ENETS Consensus Guidelines for the management of patients with liver and other distant metastases from neuroendocrine neoplasms of foregut, midgut, hindgut, and unknown primary. Neuroendocrinology 95:157–176

    Article  CAS  PubMed  Google Scholar 

  14. Ramage JK, Ahmed A, Ardill J, UK and Ireland Neuroendocrine Tumour Society et al (2012) Guidelines for the management of gastroenteropancreatic neuroendocrine (including carcinoid) tumours (NET’s). Gut 61(1):6–32

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  15. Gouya H, Vignaux O, Augui J et al (2003) CT, endoscopic sonography, and a combined protocol for preoperative evaluation of pancreatic insulinomas. AJR Am J Roentgenol 181(4):987–992

    Article  PubMed  Google Scholar 

  16. Arnold R, Chen YJ, Costa F, Mallorca Consensus Conference participants, European Neuroendocrine Tumor Society et al (2009) ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: follow-up and documentation. Neuroendocrinology 90(2):227–233

    Article  CAS  PubMed  Google Scholar 

  17. Campana D, Nori F, Piscitelli L et al (2007) Chromogranin A: is it a useful marker of neuroendocrine tumors? J Clin Oncol 25(15):1967–1973

    Article  CAS  PubMed  Google Scholar 

  18. Arnold R, Wilke A, Rinke A et al (2008) Plasma chromogranin A as marker for survival in patients with metastatic endocrine gastroenteropancreatic tumors. Clin Gastroenterol Hepatol 6(7):820–827

    Article  CAS  PubMed  Google Scholar 

  19. Kulke MH, Benson AB III, Bergsland E et al (2012) Neuroendocrine tumors. J Natl Compr Cancer Netw 10:724–764

    CAS  Google Scholar 

  20. Peppa M, Brountzos E, Economopoulos N et al (2009) Embolization as an alternative treatment of insulinoma in a patient with multiple endocrine neoplasia type 1 syndrome. Cardiovasc Intervent Radiol 32:807–811

    Article  PubMed  Google Scholar 

  21. Moore T, Peterson L, Harington D (1982) Successful arterial embolization of an insulinoma. JAMA 248:1953–1955

    Article  Google Scholar 

  22. Uflacker R (1992) Arterial embolization as definitive treatment for benign insulinoma of the pancreas. J Vasc Interv Radiol 3:441–639 discussion 644–666

    Article  Google Scholar 

  23. Rott G, Biggemann M, Pfohl M (2008) Embolization of an insulinoma of the pancreas with trisacryl gelatin microspheres as definitive treatment. Cardiovasc Intervent Radiol 31:659–662

    Article  PubMed  Google Scholar 

  24. Ben-Ishay O, Linder R, Ofer A et al (2012) Hypervascular lesion in the head of the pancreas. Preoperative angiography and selective embolization results in bloodless operation. JOP 13:671–673

    PubMed  Google Scholar 

  25. Rossi M, Orgera G, Hatzidakis A et al (2014) Minimally invasive ablation treatment for locally advanced pancreatic adenocarcinoma. Cardiovasc Intervent Radiol 37:203–210

    Article  PubMed  Google Scholar 

  26. Goldberg SN, Mallery S, Gazelle GS et al (1999) EUS-guided radiofrequency ablation in the pancreas: results in a porcine model. Gastrointest Endosc 50:392–401

    Article  CAS  PubMed  Google Scholar 

  27. Date RS, Biggins J, Paterson I et al (2005) Development and validation of an experimental model for the assessment of radiofrequency ablation of pancreatic parenchyma. Pancreas 30:266–271

    Article  PubMed  Google Scholar 

  28. Matsui Y, Nakagawa A, Kamiyama Y et al (2000) Selective thermocoagulation of unresectable pancreatic cancers by using radiofrequency capacitive heating. Pancreas 20:14–20

    Article  CAS  PubMed  Google Scholar 

  29. Limmer S, Huppertb P, Juettea V et al (2009) Radiofrequency ablation of solitary pancreatic insulinoma in a patient with episodes of severe hypoglycemia. Eur J Gastroenterol Hepatol 21:1097–1101

    Article  PubMed  Google Scholar 

  30. Akhlaghpoor S, Dahi F, Alinaghizadeh M et al (2011) CT fluoroscopy-guided transcaval radiofrequency ablation of insulinoma. J Vasc Interv Radiol 22:409–410

    Article  PubMed  Google Scholar 

  31. Wu P, Pan C, Huang Z et al (2010) Percutaneous radiofrequency ablation approach through the spleen: initial case report for pancreatic tail gastrinoma. Chin J Cancer 29:836–841

    Article  PubMed  Google Scholar 

  32. Hlavsa J, Procházka V, Kala Z et al (2011) Radiofrequency ablation of pancreatic neuroendocrine tumor. Klin Onkol 24:209–215

    CAS  PubMed  Google Scholar 

  33. Fegrachi S, Besselink MG, van Santvoort HC et al (2014) Radiofrequency ablation for unresectable locally advanced pancreatic cancer: a systematic review. HPB (Oxford) 16:119–123

    Article  Google Scholar 

  34. Chen Q, Zhu X, Chen Q et al (2013) Unresectable giant pancreatic neuro-endocrine tumor effectively treated by HIFU: a case report and a review of the literature. Pancreatology 13:634–638

    Article  PubMed  Google Scholar 

  35. Dunki-Jacobs EM, Philips P, Martin RC 2nd (2014) Evaluation of resistance as a measure of successful tumor ablation during irreversible electroporation of the pancreas. J Am Coll Surg 218(2):179–187

    Article  PubMed  Google Scholar 

  36. Scheffer HJ, Nielsen K, de Jong MC et al (2014) Irreversible electroporation for nonthermal tumor ablation in the clinical setting: a systematic review of safety and efficacy. J Vasc Interv Radiol 25(7):997–1011

    Article  PubMed  Google Scholar 

  37. Mayo SC, De Jong MC, Pulitano C et al (2010) Surgical management of hepatic neuroendocrine tumor metastasis: results from an international multi-institutional analysis. Ann Surg Oncol 17:3129–3136

    Article  PubMed  Google Scholar 

  38. John BJ, Davidson BR (2012) Treatment options for unresectable neuroendocrine liver metastases. Expert Rev Gastroenterol Hepatol 6:357–369

    Article  CAS  PubMed  Google Scholar 

  39. Frilling A, Sotiropoulos GC, Li J et al (2010) Multimodal management of neuroendocrine liver metastases. HPB (Oxford) 12:361–379

    Article  Google Scholar 

  40. McDermott EW, Guduric B, Brennan MF (1994) Prognostic variables in patients with gastrointestinal carcinoid tumours. Br J Surg 81:1007–1009

    Article  CAS  PubMed  Google Scholar 

  41. Zeitels J, Naunheim K, Kaplan EL et al (1982) Carcinoid tumors: a 37-year experience. Arch Surg 117:732–737

    Article  CAS  PubMed  Google Scholar 

  42. Panzuto F, Merola E, Rinzivillo M et al (2014) Advanced digestive neuroendocrine tumors: metastatic pattern is an independent factor affecting clinical outcome. Pancreas 43:212–218

    Article  CAS  PubMed  Google Scholar 

  43. Dromain C, de Baere T, Baudin E et al (2003) MR imaging of hepatic metastases caused by neuroendocrine tumors: comparing four techniques. AJR Am J Roentgenol 180(1):121–128

    Article  PubMed  Google Scholar 

  44. Gupta S, Johnson MM, Murthy R et al (2005) Hepatic arterial embolization and chemoembolization for the treatment of patients with metastatic neuroendocrine tumors: variables affecting response rates and survival. Cancer 104:1590–1602

    Article  PubMed  Google Scholar 

  45. Strosberg JR, Choi J, Cantor AB et al (2006) Selective hepatic artery embolization for treatment of patients with meta-static carcinoid and pancreatic endocrine tumors. Cancer Control 13:72–78

    PubMed  Google Scholar 

  46. Sofocleous CT, Petre EN, Gonen M et al (2013) Factors affecting periprocedural morbidity and mortality and long-term patient survival after arterial embolization of hepatic neuroendocrine metastases. J Vasc Interv Radiol 25:22–30

    Article  Google Scholar 

  47. Kress O, Wagner HJ, Wied M et al (2003) Transarterial chemoembolization of advanced liver metastases of neuroendocrine tumors—a retrospective single-center analysis. Digestion 68:94–101

    Article  CAS  PubMed  Google Scholar 

  48. Korse CM, Bonfrer JM, Prevoo W et al (2011) Increase of angiogenic growth factors after hepatic artery embolization in patients with neuroendocrine tumours. Tumour Biol 32(4):647–652

    Article  CAS  PubMed  Google Scholar 

  49. Liao XF, Yi JL, Li XR et al (2004) Angiogenesis in rabbit hepatic tumor after transcatheter arterial embolization. World J Gastroenterol 10(13):1885–1889

    PubMed  Google Scholar 

  50. Strosberg JR, Weber JM, Choi J et al (2012) A phase II clinical trial of sunitinib following hepatic transarterial embolization for metastatic neuroendocrine tumors. Ann Oncol 23(9):2335–2341

    Article  CAS  PubMed  Google Scholar 

  51. Ruutiainen AT, Soulen MC, Tuite CM et al (2007) Chemoembolization and bland embolization of neuroendocrine tumor metastases to the liver. J Vasc Interv Radiol 18:847–855

    Article  PubMed  Google Scholar 

  52. Pitt SC, Knuth J, Keily JM et al (2008) Hepatic neuroendocrine metastases: chemo- or bland embolization? J Gastrointest Surg 12:1951–1960

    Article  PubMed Central  PubMed  Google Scholar 

  53. Maire F, Lombard-Bohas C, O’Toole D et al (2012) Hepatic arterial embolization versus chemoembolization in the treatment of liver metastases of well-differentiated midgut endocrine tumors. A prospective randomized study. Neuroendocrinology 96:294–300

    Article  CAS  PubMed  Google Scholar 

  54. Fiore F, Del Prete M, Franco R et al (2014) Transarterial embolization (TAE) is equally effective and slightly safer than transarterial chemoembolization (TACE) to manage liver metastases in neuroendocrine tumors. Endocrine 47(1):177–182

    Article  CAS  PubMed  Google Scholar 

  55. De Baere T, Deschamps F, Teriitheau C et al (2008) Transarterial chemoembolization of liver metastases from well differentiated gastroenteropancreatic endocrine tumors with doxorubicin-eluting beads: preliminary results. J Vasc Interv Radiol 19:855–861

    Article  PubMed  Google Scholar 

  56. Gaur SK, Friese JL, Sadow CA et al (2011) Hepatic arterial chemoembolization using drug-eluting beads in gastrointestinal neuroendocrine tumor metastatic to the liver. Cardiovasc Intervent Radiol 34:566–572

    Article  PubMed  Google Scholar 

  57. Bhagat N, Reyes DK, Lin M et al (2013) Phase II study of chemoembolization with drug-elutingbeads in patients with hepatic neuroendocrine metastases: high incidence of biliary injury. Cardiovasc Intervent Radiol 36:449–459

    Article  PubMed Central  PubMed  Google Scholar 

  58. Guiu B, Deschamps F, Aho S et al (2012) Liver/biliary injuries following chemoembolisation of endocrine tumours and hepatocellular carcinoma: lipiodol vs. drug-eluting beads. J Hepatol 56(3):609–617

    Article  CAS  PubMed  Google Scholar 

  59. Kennedy AS, Dezarn WA, McNeillie P et al (2008) Radioembolization for unresectable neuroendocrine hepatic metastases using resin 90Y-microspheres: early results in 148 patients. Am J Clin Oncol 31:271–279

    Article  PubMed  Google Scholar 

  60. King J, Quinn R, Glenn DM et al (2008) Radioembolization with selective internal radiation microspheres for neuroendocrine liver metastases. Cancer 113:921–929

    Article  PubMed  Google Scholar 

  61. Cao CQ, Yan TD, Bester L et al (2010) Radioembolization with yttrium microspheres for neuroendocrine tumour liver metastases. Br J Surg 97:537–543

    Article  CAS  PubMed  Google Scholar 

  62. Saxena A, Chua TC, Bester L et al (2010) Factors predicting response and survival after yttrium-90 radioembolization of unresectable neuroendocrine tumor liver metastases: a critical appraisal of 48 cases. Ann Surg 251:910–916

    Article  PubMed  Google Scholar 

  63. Kalinowski M, Dressler M, Konig A et al (2009) Selective internal radiotherapy with yttrium-90 microspheres for hepatic metastatic neuroendocrine tumors: a prospective single center study. Digestion 79:137–142

    Article  PubMed  Google Scholar 

  64. Paprottka PM, Hoffmann RT, Haug A et al (2012) Radioembolization of symptomatic, unresectable neuroendocrine hepatic metastases using yttrium-90 microspheres. Cardiovasc Intervent Radiol 35:334–342

    Article  PubMed  Google Scholar 

  65. Rhee TK, Lewandowski RJ, Liu DM et al (2008) 90Y radioembolization for metastatic neuroendocrine liver tumors: preliminary results from a multi-institutional experience. Ann Surg 247:1029–1035

    Article  PubMed  Google Scholar 

  66. Jansen MC, Van Hillegersberg R, Schoots IG et al (2010) Cryoablation induces greater inflammatory and coagulative responses than radiofrequency ablation or laser induced thermotherapy in a rat liver model. Surgery 147:686–695

    Article  PubMed  Google Scholar 

  67. Vyleta M, Coldwell D (2011) Radioembolization in the treatment of neuroendocrine tumor metastases to the liver. Int J Hepatol 2011:785315

    Article  PubMed Central  PubMed  Google Scholar 

  68. Limouris GS, Chatziioannou A, Kontogeorgakos D et al (2008) Selective hepatic arterial infusion of In-111-DTPA-Phe1octreotide in neuroendocrine liver metastases. Eur J Nucl Med Mol Imaging 35(10):1827–1837

    Article  CAS  PubMed  Google Scholar 

  69. Auernhammer CJ, Goke B (2011) Therapeutic strategies for advanced neuroendocrine carcinomas of jejunum/ileum and pancreatic origin. Gut 60:1009–1021

    Article  CAS  PubMed  Google Scholar 

  70. Akyildiz HY, Mitchell J, Milas M et al (2010) Laparoscopic radiofrequency thermal ablation of neuroendocrine hepatic metastases: long-term follow-up. Surgery 148:1288–1293

    Article  PubMed  Google Scholar 

  71. Mazzaglia PJ, Berber E, Milas M et al (2007) Laparoscopic radiofrequency ablation of neuroendocrine liver metastases: a 10-year experience evaluating predictors of survival. Surgery 142:10–19

    Article  PubMed  Google Scholar 

  72. Martin RC, Scoggins CR, McMasters KM (2010) Safety and efficacy of microwave ablation of hepatic tumors: a prospective review of a 5-year experience. Ann Surg Oncol 17:171–178

    Article  PubMed  Google Scholar 

  73. Groeschl RT, Pilgrim CH, Hanna EM et al (2013) Microwave ablation for hepatic malignancies: a multiinstitutional analysis. Ann Surg 259(2):1195–1200

    Google Scholar 

  74. Shapiro RS, Shafir M, Sung M et al (1998) Cryotherapy of metastatic carcinoid tumors. Abdom Imaging 23:314–317

    Article  CAS  PubMed  Google Scholar 

  75. Seifert JK, Cozzi PJ, Morris DL (1998) Cryotherapy for neuroendocrine liver metastases. Semin Surg Oncol 14:175–183

    Article  CAS  PubMed  Google Scholar 

  76. Bilchik AJ, Sarantou T, Foshag LJ et al (1997) Cryosurgical palliation of metastatic neuroendocrine tumors resistant to conventional therapy. Surgery 122:1040–1047 discussion 1047–1048

    Article  CAS  PubMed  Google Scholar 

  77. Seifert JK, Morris DL (1999) World survey on the complications of hepatic and prostate cryotherapy. World J Surg 1923:109–113 discussion 113–114

    Article  Google Scholar 

Download references

Conflict of interest

Gianluigi Orgera, Miltiadis Krokidis, Matteo Cappucci, Sofia Gourtsoyianni, Marcello Andrea Tipaldi, Adam Hatzidakis, Alberto Rebonato and Michele Rossi have no conflicts of interest.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Miltiadis Krokidis.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Orgera, G., Krokidis, M., Cappucci, M. et al. Current Status of Interventional Radiology in the Management of Gastro-Entero-Pancreatic Neuroendocrine Tumours (GEP-NETs). Cardiovasc Intervent Radiol 38, 13–24 (2015). https://doi.org/10.1007/s00270-014-1005-z

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00270-014-1005-z

Keywords

Navigation